Molgenium is a German-based biopharmaceutical company that is dedicated to developing innovative therapies to address the complex medical needs of patients suffering from rare and severe diseases. The company’s personalized approach to medicine has the potential to transform healthcare and represents a major step forward in the development of innovative and effective treatments. Molgenium specializes in cell and gene therapy, which is made from a patient’s own cells, manufacturers, and product distributors. The company is focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for patients.